Correction: BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma

PDF  |  How to cite

Oncotarget. 2021; 12:1323-1324. https://doi.org/10.18632/oncotarget.28001

Metrics: PDF 915 views  |   ?  

M. Herman Chui1, Susanne K. Kjaer3,4, Kirsten Frederiksen3, Charlotte G. Hannibal3, Tian-Li Wang1, Russell Vang1,2,* and Ie-Ming Shih1,2,*

1 Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2 Department of Obstetrics & Gynecology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
3 Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
4 Gynecologic Clinic, Juliane Marie Centre, Copenhagen University Hospital, Copenhagen, Denmark
* These authors have contributed equally to this work

Published: June 22, 2021

Copyright: © 2021 Chui et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Table 2, the numbers in column 2, rows 2 and 3, were accidentally switched. The corrected Table 2 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2019; 10:6870–6878. DOI: https://doi.org/10.18632/oncotarget.27326.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28001